SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

AEON Biopharma, Inc. – ‘SC 13G/A’ on 1/17/20 re: Evolus, Inc.

On:  Friday, 1/17/20, at 5:18pm ET   ·   Accession #:  1078782-20-29   ·   File #:  5-90861

Previous ‘SC 13G’:  ‘SC 13G’ on 2/14/19   ·   Latest ‘SC 13G’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/17/20  AEON Biopharma, Inc.              SC 13G/A               1:40K  Evolus, Inc.                      Action Edgar Fil… Svc/FA

Amendment to Statement of Acquisition of Beneficial Ownership by a Passive Investor   —   Sch. 13G
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13G/A    Amendment to Statement of Acquisition of            HTML     24K 
                Beneficial Ownership by a Passive Investor                       


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 
  Schedule 13G  

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934
(Amendment No.: 1)*

 

Evolus, Inc.

(Name of Issuer)

 

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

 

30052C107

(CUSIP Number)

 

January 8, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[  ] Rule 13d-1(b)

[  ] Rule 13d-1(c)

[X] Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures in a prior cover page. 

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 


 

CUSIP No. 30052C107

13G

Page 2 of 5 Pages

 

1

NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS

(ENTITIES ONLY)

 

AEON Biopharma, Inc. – (45-4777018)

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) [  ] (b) [   ]

3

SEC USE ONLY

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

DELAWARE, USA

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

0

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

0

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [  ]

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.00%

12

TYPE OF REPORTING PERSON

 

CO


 

 

CUSIP No. 30052C107

13G

Page 3 of 5 Pages

 

Item 1(a)

Name of Issuer: 

 

 

Evolus, Inc.

 

 

Item 1(b)

Address of Issuer’s Principal Executive Offices: 

 

 

520 Newport Center Drive, Suite 1200

Newport Beach, California 92660

 

 

Item 2(a)

Name of Person Filing: 

 

 

AEON Biopharma, Inc. (f.k.a. Alphaeon Corporation) -- 45-4777018

 

 

Item 2(b)

Address of Principal Business Office or, If None, Residence 

 

 

AEON Biopharma, Inc.

4040 MacArthur Boulevard, Suite 310

Newport Beach, CA 92660

 

 

Item 2(c)

Citizenship: 

 

 

Delaware, USA

 

 

Item 2(d)

Title of Class of Securities: 

 

 

Common Stock, par value $0.00001 per share 

 

 

Item 2(e)

CUSIP Number: 

 

 

30052C107

 

 

Item 3.

If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: 

 

 

 

Not Applicable.


 

 

CUSIP No. 30052C107

13G

Page 4 of 5 Pages

 

Item 4.

Ownership 

 

 

 

(a)Amount beneficially owned: 0 

 

(b)Percent of Class: 0.0%  

 

(c)Number of shares as to which AEON Biopharma, Inc. has: 

 

(i)Sole power to vote or to direct the vote: 0 

 

(ii)Shared power to vote or to direct the vote: 0 

 

(iii)Sole power to dispose or to direct the disposition of: 0 

 

(iv)Shared power to dispose or to direct the disposition of: 0 

 

 

 Item 5.

Ownership of Five Percent or Less of a Class 

 

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

 

 

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person 

 

 

Not applicable. 

 

 

Item 7.

Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person 

 

 

 

Not applicable. 

 

 

Item 8.

Identification and Classification of Members of the Group 

 

 

Not applicable. 

 

 

Item 9.

Notice of Dissolution of Group 

 

 

Not applicable. 

 

 

Item 10.

Certifications 

 

 

Not applicable.


 

 

CUSIP No. 30052C107

13G

Page 5 of 5 Pages

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: January 17, 2020

AEON BIOPHARMA, INC.

 

 

 

 

By:

/s/ Vikram Malik

 

 

Vikram Malik, Acting President

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘SC 13G/A’ Filing    Date    Other Filings
Filed on:1/17/20
1/8/203,  4
 List all Filings 
Top
Filing Submission 0001078782-20-000029   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 8:10:36.1pm ET